NO20045460L - Behandling av T-cellemedierte autoimmune forstyrrelser - Google Patents
Behandling av T-cellemedierte autoimmune forstyrrelserInfo
- Publication number
- NO20045460L NO20045460L NO20045460A NO20045460A NO20045460L NO 20045460 L NO20045460 L NO 20045460L NO 20045460 A NO20045460 A NO 20045460A NO 20045460 A NO20045460 A NO 20045460A NO 20045460 L NO20045460 L NO 20045460L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- cell mediated
- mediated autoimmune
- autoimmune disorders
- oophoritis
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 abstract 2
- 102100032937 CD40 ligand Human genes 0.000 abstract 1
- 101000759376 Escherichia phage Mu Tail sheath protein Proteins 0.000 abstract 1
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000005963 oophoritis Diseases 0.000 abstract 1
- 206010043778 thyroiditis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Det er beskrevet anvendelse av en gp39-antagonist ved fremstilling av et medikament egnet til behandling av en T-cellemediert autoimmunsykdom valgt blant EAE (eksperimentell allergisk encefalomyelitt), diabetes type I, oophoritis og tyroiditis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/481,735 US5833987A (en) | 1995-06-07 | 1995-06-07 | Treatment of T cell mediated autoimmune disorders |
PCT/US1996/009137 WO1996040246A1 (en) | 1995-06-07 | 1996-06-06 | Treatment of t cell mediated autoimmune disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20045460L true NO20045460L (no) | 1998-02-06 |
Family
ID=23913182
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19975520A NO322391B1 (no) | 1995-06-07 | 1997-12-01 | Anvendelse av en gp39-antagonist ved fremstilling av et medikament egnet til behandling av ikke-B-lymfocytt-mediert vevsdestruksjon assosiert med multippel sklerose. |
NO20045460A NO20045460L (no) | 1995-06-07 | 2004-12-15 | Behandling av T-cellemedierte autoimmune forstyrrelser |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19975520A NO322391B1 (no) | 1995-06-07 | 1997-12-01 | Anvendelse av en gp39-antagonist ved fremstilling av et medikament egnet til behandling av ikke-B-lymfocytt-mediert vevsdestruksjon assosiert med multippel sklerose. |
Country Status (17)
Country | Link |
---|---|
US (4) | US5833987A (no) |
EP (2) | EP0831906B1 (no) |
JP (1) | JPH11507058A (no) |
KR (1) | KR100493482B1 (no) |
CN (2) | CN1827168A (no) |
AT (1) | ATE214944T1 (no) |
AU (1) | AU705623B2 (no) |
CA (1) | CA2223303A1 (no) |
DE (1) | DE69620174T2 (no) |
DK (1) | DK0831906T3 (no) |
ES (1) | ES2177791T3 (no) |
HU (1) | HUP9900857A3 (no) |
NO (2) | NO322391B1 (no) |
NZ (1) | NZ311276A (no) |
PT (1) | PT831906E (no) |
WO (1) | WO1996040246A1 (no) |
ZA (1) | ZA964851B (no) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
US7070777B1 (en) * | 1991-11-15 | 2006-07-04 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting inflammation with an antibody that binds the 5C8 protein |
IL104684A0 (en) * | 1992-02-14 | 1993-06-10 | Bristol Myers Squibb Co | The cd40cr receptor and ligands therefor |
US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
US6562629B1 (en) | 1999-08-11 | 2003-05-13 | Cedars-Sinai Medical Center | Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum |
US6861053B1 (en) * | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US5833987A (en) * | 1995-06-07 | 1998-11-10 | Trustees Of Dartmouth College | Treatment of T cell mediated autoimmune disorders |
US6440418B1 (en) * | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
US6340459B1 (en) | 1995-12-01 | 2002-01-22 | The Trustees Of Columbia University In The City Of New York | Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients |
TR199902192T2 (xx) * | 1997-01-10 | 1999-12-21 | Biogen,Inc | Anti-CDL40 bile�iklerinin tedavi ama�l� uygulama y�ntemleri |
WO1999000143A1 (en) * | 1997-06-27 | 1999-01-07 | Biogen, Inc. | Cd154 blockade therapy for autoimmune diseases |
CN100352497C (zh) * | 1998-04-03 | 2007-12-05 | 达特茅斯学院理事 | 应用特异性结合cd40cr(cd40 配体)的抗体抑制体液免疫 |
US20030077667A1 (en) * | 1999-06-01 | 2003-04-24 | Jun Tan | Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease |
US6787318B1 (en) * | 1999-06-01 | 2004-09-07 | Roskamp Research Institute, Llc | Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology |
US20070160615A1 (en) * | 1999-06-01 | 2007-07-12 | Jun Tan | Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of Alzheimer's disease |
AU2001251612A1 (en) | 2000-04-14 | 2001-10-30 | Millennium Pharmaceuticals, Inc. | Roles of jak/stat family members in tolerance induction |
US20020009444A1 (en) * | 2000-04-25 | 2002-01-24 | Idec Pharmaceuticals Corporation | Intrathecal administration of rituximab for treatment of central nervous system lymphomas |
US6797263B2 (en) | 2000-05-12 | 2004-09-28 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for achieving immune suppression |
WO2001094586A2 (en) * | 2000-06-06 | 2001-12-13 | Idec Pharmaceuticals Corporation | Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |
ATE328906T1 (de) * | 2002-06-28 | 2006-06-15 | Domantis Ltd | Dual-specifische liganden mit erhöhter halbwertszeit |
US20040146949A1 (en) * | 2002-10-25 | 2004-07-29 | Jun Tan | Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
GB0707208D0 (en) * | 2007-04-13 | 2007-05-23 | Istituto Superiore Di Sanito | Novel disease treatments |
ES2401536T3 (es) * | 2007-11-13 | 2013-04-22 | Evec Inc. | Anticuerpos monoclonales que se unen a HGM-CSF y composiciones medicinales que los comprenden |
EP2229914B1 (en) * | 2009-03-20 | 2018-05-30 | Nobel Biocare Services AG | System and method for aligning virtual models |
MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
KR101614739B1 (ko) * | 2015-12-01 | 2016-04-22 | 덕산네오룩스 주식회사 | 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치 |
MA50435A (fr) | 2017-05-24 | 2020-09-02 | Als Therapy Development Inst | Anticorps anti-ligand anti-cd40 thérapeutiques |
WO2019175332A1 (en) | 2018-03-14 | 2019-09-19 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Bh4 pathway inhibition and use thereof for treating t-cell mediated autoimmune diseases or hypersensitivity |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5690933A (en) * | 1989-05-31 | 1997-11-25 | Glaxo Wellcome Inc. | Monoclonal antibodies for inducing tolerance |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5192773A (en) * | 1990-07-02 | 1993-03-09 | Vertex Pharmaceuticals, Inc. | Immunosuppressive compounds |
US5962406A (en) * | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
IL104684A0 (en) * | 1992-02-14 | 1993-06-10 | Bristol Myers Squibb Co | The cd40cr receptor and ligands therefor |
US5571507A (en) * | 1992-02-25 | 1996-11-05 | Seragen, Inc. | Methods of treating diabetes |
US5958403A (en) * | 1992-02-28 | 1999-09-28 | Beth Israel Hospital Association | Methods and compounds for prevention of graft rejection |
WO1994028912A1 (en) * | 1993-06-10 | 1994-12-22 | The Regents Of The University Of Michigan | Cd28 pathway immunosuppression |
EP0721346B1 (en) * | 1993-09-02 | 1998-06-10 | Trustees of Dartmouth College | Methods for inducing antigen-specific t cell tolerance |
US5565491A (en) * | 1994-01-31 | 1996-10-15 | Bristol-Myers Squibb Company | Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation |
US5833987A (en) * | 1995-06-07 | 1998-11-10 | Trustees Of Dartmouth College | Treatment of T cell mediated autoimmune disorders |
-
1995
- 1995-06-07 US US08/481,735 patent/US5833987A/en not_active Expired - Lifetime
-
1996
- 1996-06-06 ES ES96921309T patent/ES2177791T3/es not_active Expired - Lifetime
- 1996-06-06 HU HU9900857A patent/HUP9900857A3/hu not_active Application Discontinuation
- 1996-06-06 CN CNA2005101286806A patent/CN1827168A/zh active Pending
- 1996-06-06 PT PT96921309T patent/PT831906E/pt unknown
- 1996-06-06 KR KR1019970708752A patent/KR100493482B1/ko not_active IP Right Cessation
- 1996-06-06 CA CA002223303A patent/CA2223303A1/en not_active Abandoned
- 1996-06-06 AU AU62559/96A patent/AU705623B2/en not_active Ceased
- 1996-06-06 WO PCT/US1996/009137 patent/WO1996040246A1/en not_active Application Discontinuation
- 1996-06-06 AT AT96921309T patent/ATE214944T1/de not_active IP Right Cessation
- 1996-06-06 NZ NZ311276A patent/NZ311276A/xx unknown
- 1996-06-06 DK DK96921309T patent/DK0831906T3/da active
- 1996-06-06 CN CN96195877A patent/CN1192156A/zh active Pending
- 1996-06-06 JP JP9501528A patent/JPH11507058A/ja active Pending
- 1996-06-06 DE DE69620174T patent/DE69620174T2/de not_active Expired - Fee Related
- 1996-06-06 EP EP96921309A patent/EP0831906B1/en not_active Expired - Lifetime
- 1996-06-06 EP EP01114411A patent/EP1161954A1/en not_active Withdrawn
- 1996-06-07 ZA ZA964851A patent/ZA964851B/xx unknown
-
1997
- 1997-12-01 NO NO19975520A patent/NO322391B1/no unknown
-
1998
- 1998-05-18 US US09/080,349 patent/US6328964B1/en not_active Expired - Lifetime
-
2001
- 2001-05-08 US US09/849,969 patent/US20020009450A1/en not_active Abandoned
-
2004
- 2004-04-21 US US10/830,310 patent/US20040197327A1/en not_active Abandoned
- 2004-12-15 NO NO20045460A patent/NO20045460L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR19990022273A (ko) | 1999-03-25 |
US20040197327A1 (en) | 2004-10-07 |
AU6255996A (en) | 1996-12-30 |
CN1192156A (zh) | 1998-09-02 |
CN1827168A (zh) | 2006-09-06 |
EP0831906B1 (en) | 2002-03-27 |
US5833987A (en) | 1998-11-10 |
EP0831906A1 (en) | 1998-04-01 |
ATE214944T1 (de) | 2002-04-15 |
ZA964851B (en) | 1997-07-29 |
HUP9900857A3 (en) | 1999-11-29 |
HUP9900857A2 (hu) | 1999-07-28 |
WO1996040246A1 (en) | 1996-12-19 |
AU705623B2 (en) | 1999-05-27 |
NO322391B1 (no) | 2006-10-02 |
NO975520L (no) | 1998-02-06 |
NZ311276A (en) | 1999-11-29 |
CA2223303A1 (en) | 1996-12-19 |
PT831906E (pt) | 2002-09-30 |
ES2177791T3 (es) | 2002-12-16 |
DE69620174D1 (de) | 2002-05-02 |
NO975520D0 (no) | 1997-12-01 |
EP1161954A1 (en) | 2001-12-12 |
DK0831906T3 (da) | 2002-05-21 |
DE69620174T2 (de) | 2002-07-18 |
US20020009450A1 (en) | 2002-01-24 |
JPH11507058A (ja) | 1999-06-22 |
US6328964B1 (en) | 2001-12-11 |
KR100493482B1 (ko) | 2005-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20045460L (no) | Behandling av T-cellemedierte autoimmune forstyrrelser | |
Comer et al. | Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers | |
DE122007000002I1 (de) | Pharmazeutische Zubereitung zur Verwendung in der Behandlung von Diabetes. | |
MA26658A1 (fr) | Derivés de valérohydrazine, procédé pour les préparer, médicament pour le traitement des maladies inflammatoires et auto-immunes les contenant, et leur utilisation pour préparer un tel médicament | |
Vignau | Preliminary assessment of a 10-day rapid detoxification programme using high dosage buprenorphine | |
CA2163118A1 (en) | Aurintricaboxylic Acid Fractions and Analogues with Anti-Angiogenic Activity and Methods of Use | |
AU6314296A (en) | Therapeutic agents and autoimmune diseases | |
EP0657167A3 (fr) | Application de l'oenothéine B pour obtenir un médicament destiné au traitement des troubles liés à l'hyperandrogénie, les compositions pharmaceutiques le contenant et un procédé de préparation à partir d'Epilobium Parviflorum. | |
Lee et al. | Patient compliance with prolonged oral altretamine treatment in relapsed ovarian cancer. | |
NO983917D0 (no) | Anvendelse av IL-7 for behandling av autoimmune sykdommer og særlig insulinavhengig diabetes mellitus | |
DE69819922D1 (de) | 2-Amino-6-methyl-7-acetyl-tetralin und pharmazeutische Zusammensetzungen zur Vorbeugung und therapeutischen Behandlung von entzündlichen und/oder Autoimmunkrankheiten | |
de Graaf et al. | The Weber-curve pitfall: effects of a forced introduction on reporting rates and reported adverse reaction profiles | |
Wittenborn et al. | The effect of minor tranquilizers on psychomotor performance | |
Reid | Project management: getting it right | |
WO2003080072A1 (en) | Preemptive prophylaxis of migraine | |
EA200301128A1 (ru) | Однократная доза ингибитора ароматазы для лечения бесплодия | |
Ginzburg et al. | The role of naltrexone in the management of drug abuse | |
WO2001086479A3 (en) | System for providing information prescriptions | |
Swerdlow et al. | Effects of Memantine on the Auditory Steady-State and Harmonic Responses to 40 Hz Stimulation Across Species | |
AU3065789A (en) | Clinical testing, monitoring and pharmaceutical compositions for treatment of auto-immune diseases | |
Goosby et al. | Medical care of HIV disease in methadone maintenance treatment | |
AU5903690A (en) | Use in therapy of 10-amino-5,6-dihydro-11h-dibenzo(b,e) azepine-6, 11-dione and derivatives as drugs for use in the treatment of urinary incontinence | |
James | D4T: new clinical data confirms benefit | |
Yates et al. | Resource-> Procedure-> Process-> Outcome Analysis (RPPOA): Preliminary Findings of Cost-Effectiveness Analysis of a Methadone Maintenance Program | |
Wilson et al. | Canadian narcotic comsumption warrants government, pharmaceutical industry and professional study. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |